Cabotegravir/Rilpivirine
Brand name: Cabenuva
Rank #260 of 500 drugs by total cost
$48.1M
Total Cost
7,384
Total Claims
$48.1M
Total Cost
316
Prescribers
$6,516
Cost per Claim
258
Beneficiaries
11,742
30-Day Fills
$152K
Avg Cost/Provider
23
Avg Claims/Provider
About Cabotegravir/Rilpivirine
Cabotegravir/Rilpivirine (sold as Cabenuva) was prescribed 7,384 times by 316 Medicare Part D providers in 2023, costing the program $48.1M. At $6,516 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 257 | Paliperidone (Paliperidone Er) | $49.3M | 129,516 |
| 258 | Sucralfate (Sucralfate) | $48.5M | 689,007 |
| 259 | Diroximel Fumarate (Vumerity) | $48.5M | 5,351 |
| 260 | Cabotegravir/Rilpivirine (Cabenuva) | $48.1M | 7,384 |
| 261 | Cenobamate (Xcopri) | $47.6M | 33,831 |
| 262 | Clozapine (Clozapine) | $47.0M | 491,951 |
| 263 | Pembrolizumab (Keytruda) | $46.9M | 3,947 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology